TL;DR — Milk thistle standardized to 70–80% silymarin (a flavonolignan complex — silybin A/B, silydianin, silychristin) has real human RCT evidence for non-alcoholic fatty liver disease (Loguercio 2012, PMID 22240442), type 2 diabetes glycemic control (Huseini 2006, PMID 17094080), and modest chemoprotection during hepatotoxic drug therapy. Standard dose 420–600 mg silymarin/day divided TID. Silybin phytosome (Siliphos, Legalon) has ~10× better bioavailabilityHow much of a compound actually reaches your bloodstream and tissues after you take it. Full glossary → than plain silymarin extract.
What milk thistle does (and why it matters)
The seed of Silybum marianum contains silymarin, a mix of flavonolignans dominated by silybin (also called silibinin). Silymarin has three well-characterized hepatocellular effects: - Antioxidant — scavenges free radicals and preserves hepatocyte glutathione - Membrane stabilization — competes with hepatotoxins (Amanita mushroom α-amanitin) for hepatocyte uptake receptors - Anti-fibrotic — inhibits hepatic stellate cell activation via TGF-β modulation
The liver's outsized role in longevity comes from its metabolic and detoxification centrality. Chronic subclinical hepatic inflammation and steatosis are increasingly recognized as major aging accelerators (via inflammagingChronic low-grade inflammation that increases with age and damages tissues silently. Full glossary →, insulin resistance, and altered bile acid signaling).
Primary hallmarks targeted: Chronic inflammation (hepatic) · Loss of proteostasis (hepatocyte membrane stability) · Deregulated nutrient sensing (insulin sensitivity)
Loguercio et al. (2012, PMID 22240442) — 138 NAFLD/NASH patients — silybin-vitamin E-phospholipid complex × 12 months — reduced hepatic fat, ALT, AST, insulin resistance vs placebo. Huseini et al. (2006, PMID 17094080) — 51 type 2 diabetics — silymarin 200 mg TID × 4 months — reduced HbA1c 1.0 percentage points more than placebo. Silybin IV is used as antidote for Amanita phalloides mushroom poisoning (Legalon SIL) in Europe.
Mechanism
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| Antioxidant (hepatic) | Preserves hepatic GSH; scavenges lipid peroxidation radicals | Inflammation |
| Membrane stabilization | Competes for OATP1B3 uptake with hepatotoxins | Proteostasis |
| Anti-fibrotic | Inhibits TGF-β → stellate cell activation | Inflammation |
| Insulin sensitivity | Reduces hepatic gluconeogenesis; improves peripheral insulin action | Nutrient sensing |
| PON1 activity | Increases paraoxonase 1 (anti-atherogenic enzyme) | Communication |
When milk thistle is worth using
Milk thistle earns a place when two or more apply:
- Elevated ALT/AST without acute hepatitis (fatty liver, chronic exposure to alcohol/hepatotoxins)
- Type 2 diabetes with poor glycemic control despite metformin
- Long-term hepatotoxic medication (methotrexate, statin, isotretinoin) — adjunct with physician
- Building a general hepatoprotective stack
Skip or defer if you have normal liver function and no risk exposure — the strongest evidence is corrective, not preventive.
Evidence summary
| Study | Design | N | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Loguercio 2012 (PMID 22240442) | RCT (NAFLD) | 138 | 12 mo | ↓ Steatosis, ↓ ALT, ↑ insulin sensitivity | B |
| Huseini 2006 (PMID 17094080) | RCT (T2D) | 51 | 4 mo | ↓ HbA1c 1.0pp vs placebo | B |
| Anushiravani 2019 meta (PMID 30589427) | Meta of NAFLD RCTs | 8 studies | 3–12 mo | Modest ALT/AST reduction; heterogeneous | B |
| Ferenci 1989 (PMID 2671116) | RCT (cirrhosis) | 170 | 41 mo | ↓ Mortality in early cirrhosis, but effect lost in later trials | C |
← Swipe for more columns →
Consensus: Tier B for NAFLD and diabetic glycemic control. Weaker for cirrhosis (early positive result not consistently reproduced). Longevity outcome data does not exist.
Where milk thistle disappoints
- Plain silymarin has poor oral bioavailability (<1%). The RCTs that showed the strongest effects used phytosome complexes (Siliphos, Silipide, Legalon) with ~10× better absorption. Cheap silymarin capsules may not match RCT dosing. - Not a replacement for addressing the cause of liver dysfunction (alcohol, obesity, viral hepatitis, hepatotoxic drugs). - Late-cirrhosis evidence is thin. Silymarin doesn't reverse established cirrhosis.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Silymarin extract (80%) | 420–600 mg/day divided TID | Basic form |
| Silybin phytosome (Siliphos) | 240–320 mg/day | Better bioavailability |
| Timing | With meals | Improved absorption |
| Duration | 4–12 months for hepatic marker changes | RCTs run 12 wk–12 mo |
Monitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| ALT / AST | ↓ 20–30% if elevated | Baseline + 3 mo | Continue; reassess at 6 mo |
| HbA1c (if diabetic) | ↓ 0.5–1.0% | Every 3 months | Combined effect with lifestyle + Rx |
| Fasting insulin | Improving | 3–6 months | — |
← Swipe for more columns →
Safety, red flags, and contraindications
- Excellent safety profile. GI upset, headache <5%.
- Not a substitute for hepatology evaluation of persistently elevated transaminases.
Do not self-start without clearance
- On any narrow-TI hepatotoxic drug (methotrexate, isotretinoin, valproic acid) — coordinate with prescribing MD, but generally safe as adjunct.
- Estrogen-sensitive cancers — silymarin has weak estrogenic activity in vitro; theoretical concern.
- Pregnancy — insufficient safety data.
- On warfarin — silymarin inhibits CYP2C9; may raise INR modestly.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Vitamin E | Loguercio 2012 used the combination; hepatoprotective additive | NAFLD stack |
| Berberine | Both improve insulin sensitivity through different mechanisms | Metabolic stack |
| NAC | Complementary hepatocyte protection (NAC replenishes GSH substrate) | Hepatoprotection |
| Choline / phosphatidylcholine | Rate-limiting for VLDL export from liver; reduces steatosis | NAFLD stack |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Warfarin | Modest CYP2C9 inhibition — potential INR rise | MD-managed INR monitoring |
| Ongoing alcohol consumption | Directly reverses the hepatoprotective benefit | Address the cause first |
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.